Alexander Gaffney

@AlecGaffney

Healthcare regulatory research 's . Previous: , . Tweets about regulation of , , ,

Washington, DC
Vrijeme pridruživanja: rujan 2009.

Tweetovi

Blokirali ste korisnika/cu @AlecGaffney

Jeste li sigurni da želite vidjeti te tweetove? Time nećete deblokirati korisnika/cu @AlecGaffney

  1. Prikvačeni tweet
    14. velj 2018.

    Well, it's day, which means it's time to repost THE GREATEST FDA WARNING LETTER EVER. Ahem: Roses are red, Violets are blue, Your product is made with "Love," yes, a ton, But that's a labeling violation under 21 CFR 101.4(a)(1)

    Poništi
  2. I cannot for the life of me understand why HHS declared a Public Health Emergency last week, and then waited until today to issue the PHE authorizing emergency use of medical products. Not sure it made a difference in timing, but still.

    Poništi
  3. 3. velj

    Amid record approvals, the FDA just established recommendations for how companies can promote biosimilar products--and how biologics companies *can't* disparage biosimilars. Tons of interesting nuggets within. For AgencyIQ subscribers:

    Poništi
  4. 31. sij

    In non-Pandemic news, the FDA has received record interest in botanical drug development (56 INDs in 2018 alone), but has only approved 2 botanical drugs in the last 15 years. Why? Lots of interesting reasons. I analyze for AgencyIQ subscribers here:

    Poništi
  5. 31. sij

    CORRECTION: Based on some sharper eyes than mine, my take isn't correct. HHS actually needs to issue *an additional* declaration before an EUA may be issued by the FDA. It seems likely, but it's not immediate. I regret the error. Page 17/18"

    Poništi
  6. 31. sij

    It's also really significant to me that this declaration doesn't use HHS's "significant potential" authority for a Public Health Emergency. It's a full Public Health Emergency. To me, that indicates that HHS missed an opportunity to address this earlier.

    Prikaži ovu nit
    Poništi
  7. 31. sij

    Also interesting about this public health emergency declaration is the language. Declares the public emergency retroactive to the 27th.

    Prikaži ovu nit
    Poništi
  8. 31. sij

    What does this mean for life sciences companies? The FDA can now issue Emergency Use Authorization (EUAs). That allows investigational products to be marketed more quickly for nCoV2020. The main beneficiary will probably be diagnostic companies. ()

    Poništi
  9. proslijedio/la je Tweet
    31. sij

    A trio of FDA guidance documents has established a framework for assessing gene therapies for rare diseases, including hemophilia and retinal disease. AgencyIQ has a deep dive into the guidance, industry comments and impacts for subscribers:

    Poništi
  10. proslijedio/la je Tweet
    31. sij

    Trump health chief tries to contain coronavirus — and White House frustration via

    Poništi
  11. 30. sij

    The WHO's declaration of a public health emergency could put pressure on HHS to make a similar declaration. AgencyIQ has published extensive analysis on why a PHE declaration matters for the FDA in particular: For subscribers:

    Poništi
  12. 30. sij

    Amid a surge in oncology drug ads, the FDA wants to know: Do viewers understand cancer terminology? Some new studies could help mold a new DTC approach for more than just cancer drugs. AgencyIQ's analysis for subscribers:

    Poništi
  13. 29. sij

    The FDA's newest web tool for PEPFAR information is generally useful, but either this data is wrong, or this is the most ridiculously weird baseline I have ever seen in my life. 220: [-----] 2: [----]

    Poništi
  14. 29. sij

    (And more analysis on the way, as we read through the FDA's Novel-length set of guidance documents. Guns, Germs and Steel; meet Genes, Editing and Orphans.)

    Prikaži ovu nit
    Poništi
  15. 29. sij

    Yesterday, the FDA unveiled what 21 CFR defines as a "metric ton of guidance documents" on gene therapy. AgencyIQ has been digging in deep. Our take on: Replication-competent virus testing: Orphan designation and "sameness":

    Prikaži ovu nit
    Poništi
  16. 29. sij

    Interestingly, the FDA may face additional (legal) challenges here. A recent citizen petition by Vifor contends the FDA lacks authority to approve complex generics as ANDAs: AgencyIQ analysis here:

    Poništi
  17. 29. sij

    Just throwing this out there to the regulatory intelligence professionals: Has anyone else not been getting emails from the Federal Register's Public Inspection service at the usual times? Like the items are new on the website, but I didn't get the normal emails.

    Poništi
  18. 28. sij

    What does the FDA's newest draft guidance document on gene therapies and the orphan drug act mean for development of gene therapies? unpacks the regulatory background, latest developments and potential impact for AgencyIQ. For subscribers:

    Poništi
  19. 28. sij
    Poništi
  20. 28. sij

    Interesting use of the word "potential" here. HHS has the legal authority to declare a Public Health Emergency based on "potential" scenarios. And it has previously, such as in the case of MERS-CoV.

    Poništi
  21. 28. sij

    We're already working on some other analyses exploring gaps in the FDA's legal and regulatory authority to address coronavirus. Have any tips or insights to add? My inbox is open. agaffney at agencyiq

    Prikaži ovu nit
    Poništi

Čini se da učitavanje traje već neko vrijeme.

Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.

    Možda bi vam se svidjelo i ovo:

    ·